CA 15-3 is a blood test that measures a protein shed by breast cells. It is the most widely used serum marker in breast cancer, primarily ordered to track how well treatment is working or to catch signs of recurrence. A normal level is generally 0 to 30 U/mL, though the number alone doesn’t confirm or rule out cancer.
The test is not used for screening or early diagnosis. Its real value lies in monitoring patients who already have a known breast cancer diagnosis, especially those with advanced disease.
What CA 15-3 Actually Measures
CA 15-3 detects a fragment of a protein called MUC1, a type of mucin that sits on the surface of many epithelial cells (the cells lining your organs, glands, and ducts). In healthy tissue, MUC1 helps with cell-to-cell communication and immune function. In breast cancer, cells produce abnormally large amounts of MUC1, and pieces of the protein break off into the bloodstream. The CA 15-3 test picks up those circulating fragments.
Because MUC1 is present on many types of epithelial cells, not just breast tissue, the marker can rise in other situations as well. That’s one reason it works better as a tracking tool than as a standalone diagnostic.
How the Test Is Used in Breast Cancer
The primary role of CA 15-3 is monitoring treatment response in patients with advanced or locally advanced breast cancer. Expert panels including the National Academy of Clinical Biochemistry and the European Group on Tumor Markers recommend routine CA 15-3 testing during therapy for this purpose. If levels drop during chemotherapy, it generally signals that treatment is working. If they stay elevated or climb, it may indicate the cancer is not responding.
Research on locally advanced breast cancer found that patients with high CA 15-3 levels before chemotherapy had significantly poorer clinical and pathological responses to treatment. More importantly, CA 15-3 levels that remained elevated after chemotherapy were an independent predictor of earlier disease recurrence, alongside factors like whether the tumor had invaded nearby lymphatic vessels and the tumor’s HER2 status.
The American Society of Clinical Oncology’s guidelines are clear on what the test should not be used for: screening healthy people, diagnosing breast cancer, or determining the stage of a new diagnosis. CA 15-3 is also not recommended as a sole decision-making tool. It’s meant to be interpreted alongside imaging, physical exams, and the full clinical picture.
Why It’s Not a Screening Tool
CA 15-3 misses too many early cancers and flags too many non-cancerous conditions to work as a screening test. In early-stage breast cancer (stages I and II), levels often remain within the normal range, making the test unreliable for catching the disease when it’s most treatable. The marker becomes far more sensitive in metastatic disease, which is why its usefulness is concentrated in the advanced setting.
Other Conditions That Raise CA 15-3
An elevated result doesn’t automatically point to cancer. Several benign conditions can push levels above the normal cutoff. In studies of non-malignant disease, significant CA 15-3 elevations appeared in 42.9% of patients with chronic hepatitis, 13.3% with liver cirrhosis, 16.7% with sarcoidosis, 9.7% with tuberculosis, and 6.7% with systemic lupus erythematosus. Liver conditions are especially notable because the liver plays a role in clearing the protein from the bloodstream, so impaired liver function can cause levels to accumulate.
On the cancer side, elevated CA 15-3 is not exclusive to breast malignancies. Elevations above 40 U/mL have been observed across epithelial cancers, particularly ovarian cancer (46% of cases, rising to 70% in metastatic ovarian cancer), liver cancer (30%), and lung cancer (26%). Some blood cancers and sarcomas can also produce mildly abnormal values. Melanoma and neurological tumors typically do not.
What Can Affect Your Results
If you take biotin supplements, sometimes labeled as vitamin B7 or sold for hair and nail health, they can interfere with the lab equipment used to run the CA 15-3 test. On certain testing platforms, biotin concentrations of 500 ng/mL caused the reported CA 15-3 value to drop by nearly 50%, making a truly elevated result appear falsely normal. Other testing systems are more resistant to this interference, but since you likely won’t know which platform your lab uses, the standard recommendation is to stop biotin supplements at least 72 hours before your blood draw.
No fasting is required for the test. It’s a simple blood draw, and results are typically reported in units per milliliter (U/mL).
Interpreting Your Results
The standard upper limit of normal is 30 U/mL. Values below that threshold are considered within the normal range. But a single number in isolation tells you very little. What matters most is the trend over time: is the level rising, falling, or stable?
A rising CA 15-3 in someone being treated for breast cancer may prompt further imaging to look for progression or recurrence. A falling level during chemotherapy is a favorable sign. A mildly elevated value in someone without a cancer diagnosis could reflect a liver condition, an autoimmune disease, or simply normal variation, and would need to be evaluated in context with other findings.
For younger breast cancer patients specifically, one study found that CA 15-3 was not an independent predictor of survival on its own. However, in the subgroup of patients whose other tumor marker (CEA) was low, CA 15-3 did provide additional prognostic information for both overall survival and disease-free survival. This reinforces the broader principle: CA 15-3 works best as one piece of a larger puzzle rather than a definitive answer by itself.